Jaypirca, 'Much-Needed' Treatment for CLL and SLL, Approved by FDA

Recently approved by the FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca “represents a meaningful advance” in treatment, as one expert explained.

Related Keywords

Adam Kittai ,Juan Alderuccio ,James Cancer Center ,Drug Administration ,Ohio University Cancer Center ,Sylvester Comprehensive Cancer Center ,University Of Miami Health System ,Miami Health System ,Educated Patient ,Leukemia ,Lymphoma ,News ,